Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder

Stefan Hinz(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Hans Krause(Charité - Universitätsmedizin Berlin), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Martin Schostak(Aturo), Kurt Miller(Charité - Universitätsmedizin Berlin), Mark Schrader(Arbeitsgemeinschaft Urologische Onkologie), Frank Christoph(Charité - Universitätsmedizin Berlin), Michèle J. Hoffmann(University Hospital of Bern)
Journal of Cancer Research and Clinical Oncology
August 10, 2007
10.1007/s00432-007-0288-8
Cited by 38

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218